Results 51 to 60 of about 3,335 (217)

Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation:effects on salivary IL-6, cortisol levels, affect, and non-judgment

open access: yes, 2020
RATIONALE: 5-methoxy-N,N-dimethyltryptamine is a psychotropic substance found in various plant and animal species and is synthetically produced. 5-methoxy-N,N-dimethyltryptamine is used in naturalistic settings for spiritual exploration, recreation, or ...
Davis, Alan K   +5 more
core   +1 more source

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

open access: yesFrontiers in Psychiatry
BackgroundDue to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) in the treatment of major depressive disorder (MDD).AimThe aim of Part A ...
Ellen James   +14 more
doaj   +1 more source

The pharmacological interaction of compounds in ayahuasca: a systematic review [PDF]

open access: yesBrazilian Journal of Psychiatry, 2020
Ayahuasca is a South American psychoactive plant brew used as traditional medicine in spiritual and in cultural rituals. This is a review of the current understanding about the pharmacological mechanisms that may be interacting in ayahuasca.
Simon Ruffell   +4 more
doaj   +1 more source

Dimethyltryptamine (DMT) - Molecule of the Month September 2019 [Archived version]

open access: yes, 2019
This is the Molecule of the Month entry for September 2019 about dimethyltryptamine.
Paul May (4181839)
core   +1 more source

Alkaloids from Fissistigma latifolium (Dunal) Merr.

open access: yesMolecules, 2010
A phytochemical study of the bark of Fissistigma latifolium (Annonaceae) yielded a new aporphine alkaloid, (-)-N-methylguattescidine (1), and eight known alkaloids: liriodenine (2), oxoxylopine (3), (-)-asimilobine (4), dimethyltryptamine (5 ...
Asmah Alias   +4 more
doaj   +1 more source

Quantitative Analysis of Substituted -Dimethyl-tryptamines in the Presence of Natural Type XII Alkaloids

open access: yesNatural Product Communications, 2012
This paper reports the qualitative and quantitative analysis (QA) of mixtures of hallucinogens, N,N -dimethyltryptamine (DMT) ( 1 ), 5-methoxy- ( 1a ) and 5-hydroxy- N,N -dimethyltryptamine ( 1b ) in the presence of β-carbolines (indole alkaloids of type
Bojidarka Ivanova, Michael Spiteller
doaj   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou   +3 more
wiley   +1 more source

Psychedelics and immunomodulation: Novel approaches and therapeutic opportunities

open access: yesFrontiers in Immunology, 2015
Classical psychedelics are psychoactive substances, which, besides their psychopharmacological activity, have also been shown to exert significant modulatory effects on immune responses by altering signaling pathways involved in inflammation, cellular ...
Attila eSzabo
doaj   +1 more source

N,N‐dimethyltryptamine affects electroencephalography response in a concentration‐dependent manner—A pharmacokinetic/pharmacodynamic analysis

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
N,N‐dimethyltryptamine (DMT) is a psychedelic substance and is being used as a research tool in investigations of the neurobiology behind the human consciousness using different brain imaging techniques.
Emma Eckernäs   +4 more
doaj   +1 more source

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy